Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Compass Pathways’ Phase 3 COMP360 study readout lays down its first marker.</li><li>Compass Pathways’ (NASDAQ:CMPS) much anticipated top-line Part A readout of its COMP005 pivotal two-arm trial for its lead psilocybin-based monotherapy candidate for treatment-resistant depression (TRD), COMP360, has produced a statistically significant (p-value of &lt;0.001) and clinically meaningful -3.6 mean difference in the MADRS scale comparing a one-time administered 25mg dose of COMP360 with placebo at six weeks in a 258-participant study.</li><li>Based on a statement from the independent Data and Safety Monitoring Board (DSMB), the Part A study resulted in no new or unexpected safety findings.</li></ul>

Compass Pathways’ Phase 3 COMP360 study readout lays down its first marker.Compass Pathways’ (NASDAQ:CMPS) much anticipated top-line Part A readout of its COMP005 pivotal two-arm trial for its lead psilocybin-based monotherapy candidate for treatment-resistant depression (TRD), COMP360, has produced a statistically significant (p-value of &lt;0.001) and clinically meaningful -3.6 mean difference in the MADRS scale comparing a one-time administered 25mg dose of COMP360 with placebo at six weeks in a 258-participant study.Based on a statement from the independent Data and Safety Monitoring Board (DSMB), the Part A study resulted in no new or unexpected safety findings.

Cybin, Inc: Not All Psychedelic Treatments for Depression Are Created Equal

<ul><li>Cybin announces largest psychedelic funding agreement to date.</li><li>Cybin has entered an innovative funding agreement with High Trail Special Situations LLC, an investment fund managed by High Trail Capital (HT), a hedge fund known for its experience in complex and innovative financing solutions for small-cap and early- stage public companies across a broad spectrum of sectors.</li><li>Through its arrangement with HT, Cybin effectively creates a capital reserve of up to $500 million from which it can draw funds to advance its late-stage clinical developments, CYB003 and CYB004, to potential commercialization. </li></ul>

Cybin announces largest psychedelic funding agreement to date.Cybin has entered an innovative funding agreement with High Trail Special Situations LLC, an investment fund managed by High Trail Capital (HT), a hedge fund known for its experience in complex and innovative financing solutions for small-cap and early- stage public companies across a broad spectrum of sectors.Through its arrangement with HT, Cybin effectively creates a capital reserve of up to $500 million from which it can draw funds to advance its late-stage clinical developments, CYB003 and CYB004, to potential commercialization. 

Cybin, Inc: Up To $500 Million Financing Deal Exudes Strong Confidence...

<ul><li>Interventional psychiatry clinic landscape evolving for the better.</li><li>The interventional psychiatry landscape has significantly evolved over the past five years, with the emergence of ~5,000 clinics or mental health centers offering a range of services to patients from ECT and TMS to esketamine and regular ketamine.</li><li>From Cybin’s interactions with these centers, they appear to be well prepared for potential dosing and treatment with psychedelics like Cybin’s CYB003 as they come to market. </li></ul>

Interventional psychiatry clinic landscape evolving for the better.The interventional psychiatry landscape has significantly evolved over the past five years, with the emergence of ~5,000 clinics or mental health centers offering a range of services to patients from ECT and TMS to esketamine and regular ketamine.From Cybin’s interactions with these centers, they appear to be well prepared for potential dosing and treatment with psychedelics like Cybin’s CYB003 as they come to market. 

Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch

Cybin, Inc. - The Strategic Approach to Formulating a Successful CYB003 Launch

<ul><li>Taking care of business in the present and future. Cybin continues to move its commercialization preparation plans forward with the announcement of another important partnership, this time with Thermo Fisher Scientific (NYSE: TMO), a leading life sciences service provider offering Contract Development and Manufacturing Organization (CDMO) services.</li><li>To this end, Cybin has engaged Thermo to not only supply both the drug substance and drug product capsules for its ongoing Phase 3 CYB003 program in major depressive disorder (MDD), but also for the potential commercial manufacturing of CYB003 if approved.</li><li>Tariff protection. In this agreement, CYB003 will be manufactured in Thermo’s US sites in South Carolina and Ohio and will thus be protected from tariffs should the Trump administration proceed to apply them to pharmaceutical products as it has threatened.</li></ul>

Taking care of business in the present and future. Cybin continues to move its commercialization preparation plans forward with the announcement of another important partnership, this time with Thermo Fisher Scientific (NYSE: TMO), a leading life sciences service provider offering Contract Development and Manufacturing Organization (CDMO) services.To this end, Cybin has engaged Thermo to not only supply both the drug substance and drug product capsules for its ongoing Phase 3 CYB003 program in major depressive disorder (MDD), but also for the potential commercial manufacturing of CYB003 if approved.Tariff protection. In this agreement, CYB003 will be manufactured in Thermo’s US sites in South Carolina and Ohio and will thus be protected from tariffs should the Trump administration proceed to apply them to pharmaceutical products as it has threatened.

Cybin, Inc: Covering All Bases as Commercialization Preparations Continue

Canada

Cybin Inc. is a life sciences company. The Company focuses on psychedelic drug development, unique delivery mechanisms, improved novel compounds, and protocols. Cybin serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cybin (CYBN CN)

Cybin, Inc: Not All Psychedelic Treatments for Depression Are Created Equal

Based on a statement from the independent Data and Safety Monitoring Board (DSMB), the Part A study resulted in no new or unexpected safety findings.

Water Tower Research

Cybin, Inc: Up To $500 Million Financing Deal Exudes Strong Confidence...

This stands to be potentially the largest funding exercise undertaken by a novel psychedelic-based drug developer to date.

Water Tower Research

Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch

From Cybin’s interactions with these centers, they appear to be well prepared for potential dosing and treatment with psychedelics like Cybin’s...

Water Tower Research

Cybin, Inc. - The Strategic Approach to Formulating a Successful CYB003 Launch

rom Cybin’s interactions with these centers, they appear to be well prepared for potential dosing and treatment with psychedelics like Cybin’s...

Water Tower Research

Cybin, Inc: Covering All Bases as Commercialization Preparations Continue

Cybin continues to move its commercialization preparation plans forward with the announcement of another important partnership, this time with...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)